Weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia

Introduction Weekly iron-folic acid (IFA) supplements are recommended for all menstruating women in countries where anaemia prevalence is >20%. Anaemia caused by folate deficiency is low worldwide, and the need to include folic acid is in question. Including folic acid might reduce the risk of a...

Full description

Bibliographic Details
Main Authors: Samson, Kaitlyn L. I ., Loh, Su Peng, Lee, Siew Siew, Sulistyoningrum, Dian C., Khor, Geok Lin, Mohd Shariff, Zalilah, Isma, Irmi Zarina, Yelland, Lisa N., Leemaqz, Shalem, Makrides, Maria, Hutcheon, Jennifer A., Roche, Marion L., Karakochuk, Crystal D., Green, Timothy J.
Format: Article
Published: BMJ Group 2020
Online Access:http://psasir.upm.edu.my/id/eprint/86515/
_version_ 1848860227294724096
author Samson, Kaitlyn L. I .
Loh, Su Peng
Lee, Siew Siew
Sulistyoningrum, Dian C.
Khor, Geok Lin
Mohd Shariff, Zalilah
Isma, Irmi Zarina
Yelland, Lisa N.
Leemaqz, Shalem
Makrides, Maria
Hutcheon, Jennifer A.
Roche, Marion L.
Karakochuk, Crystal D.
Green, Timothy J.
author_facet Samson, Kaitlyn L. I .
Loh, Su Peng
Lee, Siew Siew
Sulistyoningrum, Dian C.
Khor, Geok Lin
Mohd Shariff, Zalilah
Isma, Irmi Zarina
Yelland, Lisa N.
Leemaqz, Shalem
Makrides, Maria
Hutcheon, Jennifer A.
Roche, Marion L.
Karakochuk, Crystal D.
Green, Timothy J.
author_sort Samson, Kaitlyn L. I .
building UPM Institutional Repository
collection Online Access
description Introduction Weekly iron-folic acid (IFA) supplements are recommended for all menstruating women in countries where anaemia prevalence is >20%. Anaemia caused by folate deficiency is low worldwide, and the need to include folic acid is in question. Including folic acid might reduce the risk of a neural tube defect (NTD) should a woman become pregnant. Most weekly supplements contain 0.4 mg folic acid; however, WHO recommends 2.8 mg because it is seven times the daily dose effective in reducing NTDs. There is a reluctance to switch to supplements containing 2.8 mg of folic acid because of a lack of evidence that this dose would prevent NTDs. Our aim was to investigate the effect of two doses of folic acid, compared with placebo, on red blood cell (RBC) folate, a biomarker of NTD risk. Methods We conducted a three-arm double-blind efficacy trial in Malaysia. Non-pregnant women (n=331) were randomised to receive 60 mg iron and either 0, 0.4, or 2.8 mg folic acid once weekly for 16 weeks. Results At 16 weeks, women receiving 0.4 mg and 2.8 mg folic acid per week had a higher mean RBC folate than those receiving 0 mg (mean difference (95% CI) 84 (54 to 113) and 355 (316 to 394) nmol/L, respectively). Women receiving 2.8 mg folic acid had a 271 (234 to 309) nmol/L greater mean RBC folate than those receiving 0.4 mg. Moreover, women in the 2.8 mg group were seven times (RR 7.3, 95% CI 3.9 to 13.7; p[removed]748 nmol/L, a concentration associated with a low risk of NTD, compared with the 0.4 mg group. Conclusion Weekly IFA supplements containing 2.8 mg folic acid increases RBC folate more than those containing 0.4 mg. Increased availability and access to the 2.8 mg formulation is needed. Trail registration number This trial is registered with the Australian New Zealand Clinical Trial Registry (ACTRN12619000818134).
first_indexed 2025-11-15T12:41:53Z
format Article
id upm-86515
institution Universiti Putra Malaysia
institution_category Local University
last_indexed 2025-11-15T12:41:53Z
publishDate 2020
publisher BMJ Group
recordtype eprints
repository_type Digital Repository
spelling upm-865152023-11-06T08:46:10Z http://psasir.upm.edu.my/id/eprint/86515/ Weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia Samson, Kaitlyn L. I . Loh, Su Peng Lee, Siew Siew Sulistyoningrum, Dian C. Khor, Geok Lin Mohd Shariff, Zalilah Isma, Irmi Zarina Yelland, Lisa N. Leemaqz, Shalem Makrides, Maria Hutcheon, Jennifer A. Roche, Marion L. Karakochuk, Crystal D. Green, Timothy J. Introduction Weekly iron-folic acid (IFA) supplements are recommended for all menstruating women in countries where anaemia prevalence is >20%. Anaemia caused by folate deficiency is low worldwide, and the need to include folic acid is in question. Including folic acid might reduce the risk of a neural tube defect (NTD) should a woman become pregnant. Most weekly supplements contain 0.4 mg folic acid; however, WHO recommends 2.8 mg because it is seven times the daily dose effective in reducing NTDs. There is a reluctance to switch to supplements containing 2.8 mg of folic acid because of a lack of evidence that this dose would prevent NTDs. Our aim was to investigate the effect of two doses of folic acid, compared with placebo, on red blood cell (RBC) folate, a biomarker of NTD risk. Methods We conducted a three-arm double-blind efficacy trial in Malaysia. Non-pregnant women (n=331) were randomised to receive 60 mg iron and either 0, 0.4, or 2.8 mg folic acid once weekly for 16 weeks. Results At 16 weeks, women receiving 0.4 mg and 2.8 mg folic acid per week had a higher mean RBC folate than those receiving 0 mg (mean difference (95% CI) 84 (54 to 113) and 355 (316 to 394) nmol/L, respectively). Women receiving 2.8 mg folic acid had a 271 (234 to 309) nmol/L greater mean RBC folate than those receiving 0.4 mg. Moreover, women in the 2.8 mg group were seven times (RR 7.3, 95% CI 3.9 to 13.7; p[removed]748 nmol/L, a concentration associated with a low risk of NTD, compared with the 0.4 mg group. Conclusion Weekly IFA supplements containing 2.8 mg folic acid increases RBC folate more than those containing 0.4 mg. Increased availability and access to the 2.8 mg formulation is needed. Trail registration number This trial is registered with the Australian New Zealand Clinical Trial Registry (ACTRN12619000818134). BMJ Group 2020 Article PeerReviewed Samson, Kaitlyn L. I . and Loh, Su Peng and Lee, Siew Siew and Sulistyoningrum, Dian C. and Khor, Geok Lin and Mohd Shariff, Zalilah and Isma, Irmi Zarina and Yelland, Lisa N. and Leemaqz, Shalem and Makrides, Maria and Hutcheon, Jennifer A. and Roche, Marion L. and Karakochuk, Crystal D. and Green, Timothy J. (2020) Weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia. BMJ Global Health, 5 (12). pp. 1-9. ISSN 2059-7908 https://gh.bmj.com/content/5/12/e003897 10.1136/bmjgh-2020-003897
spellingShingle Samson, Kaitlyn L. I .
Loh, Su Peng
Lee, Siew Siew
Sulistyoningrum, Dian C.
Khor, Geok Lin
Mohd Shariff, Zalilah
Isma, Irmi Zarina
Yelland, Lisa N.
Leemaqz, Shalem
Makrides, Maria
Hutcheon, Jennifer A.
Roche, Marion L.
Karakochuk, Crystal D.
Green, Timothy J.
Weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia
title Weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia
title_full Weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia
title_fullStr Weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia
title_full_unstemmed Weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia
title_short Weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia
title_sort weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in malaysia
url http://psasir.upm.edu.my/id/eprint/86515/
http://psasir.upm.edu.my/id/eprint/86515/
http://psasir.upm.edu.my/id/eprint/86515/